Avacta Group Plc (AVCTF)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.5 Million GBP | 136.24% |
| 2022 | -17.93 Million GBP | 26.75% |
| 2021 | -24.48 Million GBP | 5.28% |
| 2020 | -25.85 Million GBP | -224.57% |
| 2019 | -7.96 Million GBP | -52.59% |
| 2018 | -5.22 Million GBP | 43.05% |
| 2017 | -9.16 Million GBP | 3.73% |
| 2016 | -9.52 Million GBP | -29.89% |
| 2015 | -7.33 Million GBP | 36.15% |
| 2014 | -11.48 Million GBP | -1872.51% |
| 2013 | -582 Thousand GBP | 86.11% |
| 2012 | -4.19 Million GBP | -136.78% |
| 2011 | -1.77 Million GBP | -24.91% |
| 2010 | -1.41 Million GBP | -66.9% |
| 2009 | -849 Thousand GBP | 19.6% |
| 2008 | -1.05 Million GBP | 57.33% |
| 2007 | -2.47 Million GBP | -7883.87% |
| 2006 | -31 Thousand GBP | 29.55% |
| 2005 | -44 Thousand GBP | 69.44% |
| 2004 | -144 Thousand GBP | -144.86% |
| 2003 | 321 Thousand GBP | -50.31% |
| 2002 | 646 Thousand GBP | 19.63% |
| 2001 | 540 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -3.61 Million GBP | -115.13% |
| 2023 Q3 | 23.91 Million GBP | 761.58% |
| 2023 FY | 6.5 Million GBP | 136.24% |
| 2023 Q4 | 6.5 Million GBP | -72.82% |
| 2023 Q1 | 23.89 Million GBP | 233.19% |
| 2022 Q4 | -17.93 Million GBP | -190.59% |
| 2022 FY | -17.93 Million GBP | 26.75% |
| 2022 Q1 | -13.04 Million GBP | 46.73% |
| 2022 Q2 | -12.18 Million GBP | 6.57% |
| 2022 Q3 | 19.8 Million GBP | 262.48% |
| 2021 Q3 | -24.77 Million GBP | 17.55% |
| 2021 Q4 | -24.48 Million GBP | 1.17% |
| 2021 FY | -24.48 Million GBP | 5.28% |
| 2021 Q1 | -30.35 Million GBP | -17.41% |
| 2021 Q2 | -30.05 Million GBP | 0.99% |
| 2020 Q3 | -26.14 Million GBP | 51.34% |
| 2020 Q1 | -53.88 Million GBP | 0.0% |
| 2020 Q2 | -53.71 Million GBP | 0.3% |
| 2020 Q4 | -25.85 Million GBP | 1.11% |
| 2020 FY | -25.85 Million GBP | -224.57% |
| 2019 FY | -7.96 Million GBP | -52.59% |
| 2019 Q1 | -6.5 Million GBP | 44.8% |
| 2019 Q2 | -6.5 Million GBP | 0.0% |
| 2018 Q4 | -11.78 Million GBP | 0.0% |
| 2018 FY | -5.22 Million GBP | 43.05% |
| 2018 Q2 | -5.22 Million GBP | 0.0% |
| 2018 Q1 | -5.22 Million GBP | 36.92% |
| 2017 Q1 | -9.16 Million GBP | 17.66% |
| 2017 FY | -9.16 Million GBP | 3.73% |
| 2017 Q4 | -8.27 Million GBP | 0.0% |
| 2017 Q3 | -8.27 Million GBP | 9.72% |
| 2017 Q2 | -9.16 Million GBP | 0.0% |
| 2016 Q1 | -9.52 Million GBP | 61.88% |
| 2016 FY | -9.52 Million GBP | -29.89% |
| 2016 Q3 | -11.13 Million GBP | -16.92% |
| 2016 Q4 | -11.13 Million GBP | 0.0% |
| 2016 Q2 | -9.52 Million GBP | 0.0% |
| 2015 FY | -7.33 Million GBP | 36.15% |
| 2015 Q3 | -24.97 Million GBP | -240.76% |
| 2015 Q1 | -7.33 Million GBP | 6.7% |
| 2015 Q2 | -7.33 Million GBP | 0.0% |
| 2015 Q4 | -24.97 Million GBP | 0.0% |
| 2014 Q3 | -7.85 Million GBP | 31.57% |
| 2014 FY | -11.48 Million GBP | -1872.51% |
| 2014 Q1 | -11.48 Million GBP | -253.34% |
| 2014 Q2 | -11.48 Million GBP | 0.0% |
| 2014 Q4 | -7.85 Million GBP | 0.0% |
| 2013 Q4 | -3.24 Million GBP | 0.0% |
| 2013 Q1 | -582 Thousand GBP | 71.73% |
| 2013 Q2 | -582 Thousand GBP | 0.0% |
| 2013 FY | -582 Thousand GBP | 86.11% |
| 2013 Q3 | -3.24 Million GBP | -458.25% |
| 2012 Q4 | -2.05 Million GBP | 0.0% |
| 2012 Q2 | -4.19 Million GBP | 0.0% |
| 2012 Q3 | -2.05 Million GBP | 50.87% |
| 2012 FY | -4.19 Million GBP | -136.78% |
| 2011 FY | -1.77 Million GBP | -24.91% |
| 2011 Q4 | -5.81 Million GBP | 0.0% |
| 2011 Q2 | -1.77 Million GBP | 0.0% |
| 2010 Q4 | -2.51 Million GBP | 0.0% |
| 2010 Q2 | -1.41 Million GBP | 0.0% |
| 2010 FY | -1.41 Million GBP | -66.9% |
| 2009 Q4 | -1.29 Million GBP | 0.0% |
| 2009 Q2 | -849 Thousand GBP | 0.0% |
| 2009 FY | -849 Thousand GBP | 19.6% |
| 2008 FY | -1.05 Million GBP | 57.33% |
| 2008 Q4 | -1.11 Million GBP | 0.0% |
| 2008 Q2 | -1.05 Million GBP | 0.0% |
| 2007 Q4 | -1.87 Million GBP | 0.0% |
| 2007 FY | -2.47 Million GBP | -7883.87% |
| 2006 FY | -31 Thousand GBP | 29.55% |
| 2006 Q1 | -31 Thousand GBP | 0.0% |
| 2006 Q3 | - GBP | 0.0% |
| 2005 FY | -44 Thousand GBP | 69.44% |
| 2005 Q3 | -326 Thousand GBP | 0.0% |
| 2005 Q1 | -44 Thousand GBP | 0.0% |
| 2004 FY | -144 Thousand GBP | -144.86% |
| 2004 Q1 | -144 Thousand GBP | 0.0% |
| 2004 Q3 | -276 Thousand GBP | 0.0% |
| 2003 FY | 321 Thousand GBP | -50.31% |
| 2003 Q3 | -659 Thousand GBP | 0.0% |
| 2002 FY | 646 Thousand GBP | 19.63% |
| 2001 FY | 540 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 58.758% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -57.867% |
| SQZ Biotechnologies Company | -36.23 Million USD | 117.94% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 84.808% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 203.116% |
| Mesoblast Limited | 55.85 Million USD | 88.362% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -601.154% |
| Genus plc | 190.6 Million USD | 96.589% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -190.764% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -435.552% |
| Marizyme, Inc. | 18.56 Million USD | 64.99% |
| ContraFect Corporation | -6.02 Million USD | 207.883% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -856.03% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -4728.468% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -462.648% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -189.934% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -18.159% |
| MultiCell Technologies, Inc. | 90.04 USD | -7220025.5% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 985.722% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 49.784% |
| EV Biologics, Inc. | 1.36 Million USD | -375.229% |
| Q BioMed Inc. | 4.06 Million USD | -60.123% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 78.723% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -944.566% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -545.122% |
| Biomind Labs Inc. | 711.4 Thousand USD | -813.829% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 94.079% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 49.237% |
| Skye Bioscience, Inc. | -5.72 Million USD | 213.626% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -655.719% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -4550.082% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -15.095% |
| IMV Inc. | 7.67 Million USD | 15.247% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -32622.61% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -195.234% |
| GB Sciences, Inc. | 1.74 Million USD | -272.056% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 3637.228% |
| HST Global, Inc. | 96.79 Thousand USD | -6616.396% |
| CSL Limited | 10.52 Billion USD | 99.938% |
| Halberd Corporation | 144.72 Thousand USD | -4392.092% |
| Enzolytics Inc. | 981.65 Thousand USD | -562.248% |
| Resverlogix Corp. | 6.45 Million USD | -0.775% |
| Affymax, Inc. | -5.59 Million USD | 216.152% |
| SYBLEU INC | 473.71 Thousand USD | -1272.347% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1065.846% |
| argenx SE | -2.02 Billion USD | 100.32% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 85.032% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 113.828% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -140.012% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 173.541% |
| AVAX Technologies, Inc. | -5.9 Million USD | 210.127% |
| Zenith Capital Corp. | 10.06 Thousand USD | -64496.592% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.613% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3143.495% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -172.461% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -3851.76% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 89.263% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -225.149% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 352.954% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1707.289% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 67.937% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 35589.688% |
| BioStem Technologies, Inc. | 4.47 Million USD | -45.371% |
| ONE Bio Corp. | 9.04 Million USD | 28.087% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3130.247% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 496359.618% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -3052.505% |
| Agentix Corp. | 37.63 Thousand USD | -17175.653% |
| LadRx Corporation | -2.03 Million USD | 419.229% |
| Cell Source, Inc. | 9.23 Million USD | 29.582% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 31955.16% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -923.511% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -923.511% |
| NovAccess Global Inc. | 2.17 Million USD | -198.421% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 8.061% |
| Itoco Inc. | 228.3 Thousand USD | -2747.507% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -4680.534% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -31.148% |
| Kadimastem Ltd | -253.1 Thousand USD | 2668.53% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1517.772% |
| CytoDyn Inc. | 20.26 Million USD | 67.915% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1004891.499% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1242.538% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 70242.021% |
| Qrons Inc. | 351.42 Thousand USD | -1749.887% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 15.637% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2704.359% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2031.476% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -45.86% |
| International Stem Cell Corporation | 2.59 Million USD | -151.004% |
| Bioxytran, Inc. | 1.89 Million USD | -242.354% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -10316.101% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -198.088% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -89.313% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 23.992% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -741.437% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 620.08% |
| Neutra Corp. | 52.18 Thousand USD | -12357.127% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 361.189% |
| PureTech Health plc | -167.19 Million USD | 103.888% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2754.467% |
| IXICO plc | -4.44 Million USD | 246.268% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 50.821% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 88.148% |
| CSL Limited | 10.52 Billion USD | 99.938% |
| Cellectis S.A. | -43.81 Million USD | 114.836% |